Physician profile
Nancy H Kim
NPI 1396955076
$3,150.21
in general payments reported to CMS, 2019-2025
26 companies · $437 in 2025
The $437 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $854 · 2020: $373 · 2021: $1,327 · 2022: $137 · 2023: $23.50 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $437 · Education: $23.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $436.68 |
| Education | $23.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,024.75 | 2019-2021 | |
| Abiomed | $406.95 | 2025 | |
| Novartis Pharmaceuticals Corporation | $211.89 | 2019-2020 | |
| Genentech USA, INC. | $192.12 | 2019-2022 | |
| Abbvie INC. | $167.86 | 2019-2020 | |
| Medtronic Vascular, INC. | $163.09 | 2019 | |
| Lilly USA, LLC | $157.30 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $112.71 | 2019-2022 | |
| Bard Peripheral Vascular, INC. | $112.62 | 2021 | |
| Sun Pharmaceutical Industries INC. | $99.83 | 2019-2021 | |
| Ucb, INC. | $78.96 | 2019-2021 | |
| Dermira, INC. | $67.51 | 2019-2020 | |
| Leo Pharma INC. | $65.55 | 2019 | |
| Genzyme Corporation | $44.21 | 2019-2025 | |
| Janssen Biotech, INC. | $42.62 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $36.27 | 2019-2021 | |
| Dusa Pharmaceuticals, INC. | $25.66 | 2019 | |
| Kyowa Kirin, INC. | $23.50 | 2023 | Poteligeo |
| Mayne Pharma Commercial LLC | $22.13 | 2019 | |
| Biofrontera INC. | $21.11 | 2021 | |
| Acell, INC. | $19.51 | 2020 | |
| Glenmark Therapeutics INC. | $15.00 | 2019 | |
| Paratek Pharmaceuticals, INC. | $14.82 | 2021 | |
| Epi Health, LLC | $12.92 | 2020 | |
| Pfizer INC. | $11.32 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.